Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes.~* Have a body weight of \>=50 kg.~Exclusion Criteria:~* Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.~* Have participated in this study previously, or any other study using exenatide or other GLP-1 analogs.~* Are treated with any exogenous insulin within 3 months of screening.~* Are continuously treated with any of the following excluded medications within 3 months of screening (more than 7 days per 1 month): \*drugs that directly affect gastrointestinal motility, including Nauzelin® (domperidone), Primperan®/Terperan® (metoclopramide), Ganaton® (itopride), Acenalin® (cisapride), Gasmotin® (mosapride), or Cerekinon® (trimebutine).~* Have characteristics contraindicating for concomitant medication, according to product-specific label.~* Have severe allergy or hypersensitivity to any drug.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide 5 mcg/exenatide 10 mcg (Type: EXPERIMENTAL): None
- Exenatide 5 mcg/exenatide 5 mcg (Type: EXPERIMENTAL): None
- Exenatide 2.5 mcg/exenatide 2.5 mcg (Type: EXPERIMENTAL): None
- Placebo/placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).